65,437 trials
Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population — 2; 1; 0; 1 participants
Peripheral Arterial Disease
Primary: Change From Baseline in Saphenous Vein Bypass Graft Vasodilation — 5.28 vein bypass graft size increase (%)
Kidney Transplant
Primary: Graft Survival — 13; 7 participants — p=0.849
Glioblastoma Multiforme
Primary: Progression-free Survival Rate at 6 Months — 15.4 Percentage of participants
Cardiovascular Disease
Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) — 2; 1; 0 Participants
Metastatic Breast Cancer
Primary: Abscopal Response Rate — 11; 12 Participants
Prostate Cancer
Primary: Pca Risk-related Knowledge — 6.92; 7.19 units on a scale
HAART-induced Lipodystrophy and Metabolic Syndrome
Primary: Serum Lipid Levels — 228.8; 219.7; 113.0; 105.7 mg/dl
Chronic Kidney Diseases
Primary: Correlation Coefficient (r) Between Serum C-Reactive Protein (CRP) Level and Methoxy Polyethylene Glycol-Epoetin Beta Dose — 0.1485 correlation coefficient
Chronic Hepatitis C · Hepatitis C Virus · HCV
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks Post-treatment — 100; 97.4; 96.3; 100 percentage of participants
Diabetes Type 2
Primary: Change From Baseline in the Unmet Behaviors/Goals That Were Not Achieved at Year 1 — -1.5; -1.7; -1.1 incomplete behaviors/goals — p=<0.0001
Placenta Accreta
Primary: Loss of the Retro Placental Sonolucent Zone by 2D Grayscale Ultrasonography — 12; 19 participants
Atherosclerosis
Primary: Flow-mediated, Endothelium-dependent Vasodilation — 6.8; 8.7 percentage vasodilation
Hodgkin Disease
Primary: Complete Remission Rate — 73.6 percentage of participants
Depression
Primary: Hamilton Depression Rating Scale — 18.75; 19.68 units on a scale — p=<.26